Skip Navigation


Brain Advance Access originally published online on July 16, 2009
Brain 2009 132(8):2002-2004; doi:10.1093/brain/awp184
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
132/8/2002    most recent
awp184v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Rosenberg, P. B.
Right arrow Articles by Hillis, A. E.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rosenberg, P. B.
Right arrow Articles by Hillis, A. E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author (2009). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Scientific Commentary

Biomarkers for Alzheimer's disease: ready for the next step

Paul B. Rosenberg1 and Argye E. Hillis2

1Psychiatry and Behavioral Sciences, Division of Geriatric Psychiatry and Neuropsychiatry, Johns Hopkins University School of Medicine, Johns Hopkins Bayview Medical Center, 5300 Alpha Commons Drive, AC4 Baltimore, MD 21224, USA 2Department of Neurology, Cerebrovascular Division, Johns Hopkins University School of Medicine, Meyer 6-113, 600 N. Wolf Street, Baltimore, MD 21287, USA

prosenb9@jhmi.edu; argye@jhmi.edu

The first 150 words of the full text of this article appear below.

As potential disease-modifying treatments for Alzheimer's disease advance into phase II and III human trials, it is apparent that biomarker development will be needed for several reasons. The most relevant of these include the ability to detect treatment response sensitively, to improve understanding of the effect of drugs that target disease mechanisms, and to identify Alzheimer's disease in its pre-clinical stage. We have reviewed several recent papers published in Brain, which address biomarker development in Alzheimer's disease, and use their findings to suggest further research.

Some of these studies are early results from the Alzheimer's Disease Neuroimaging Initiative (ADNI), a large multi-centre trial of biomarker modalities in patients with Alzheimer's disease, mild cognitive impairment (MCI) and cognitively healthy older controls with an emphasis on standardized imaging techniques across centres. Nestor et al. (2008Go) measured ventricular volume changes over time and found that MCI subjects had a faster . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?